Literature DB >> 20605283

[Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].

N Belkahla1, H Kchir, N Maamouri, H Ouerghi, F B Hariz, S Chouaib, H Chaabouni, N B Mami.   

Abstract

Hepatitis C viral infection can be associated with other infectious diseases including viral and bacterial infections such as tuberculosis. Mycobacterium tuberculosis infection may be latent for many years and revealed during an immunodeficiency state. The responsibility of antiviral treatment in the reactivation of tuberculosis is controversial. We report two cases of tuberculous reactivation during bitherapy with pegylated interferon and ribavirin for chronic hepatitis C. A rapid viral response was obtained in both cases. Tuberculous reactivation occurred at 12 and 13 weeks of antiviral treatment, respectively. Tuberculosis involved urinary tract in one patient and lymph nodes in the other. Antituberculous treatment was given and antiviral treatment maintained. The outcome of tuberculosis was favourable and a sustained viral response was obtained for both patients.
Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605283     DOI: 10.1016/j.revmed.2009.11.017

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  10 in total

Review 1.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  Tuberculosis screening before anti-hepatitis C virus therapy in prisons.

Authors:  Sergio Babudieri; Andrea Soddu; Monica Murino; Paola Molicotti; Alberto A Muredda; Giordano Madeddu; Alessandro G Fois; Stefania Zanetti; Pietro Pirina; Maria Stella Mura
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

3.  Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics.

Authors:  Anca Dorhoi; Vladimir Yeremeev; Geraldine Nouailles; January Weiner; Sabine Jörg; Ellen Heinemann; Dagmar Oberbeck-Müller; Julia K Knaul; Alexis Vogelzang; Stephen T Reece; Karin Hahnke; Hans-Joachim Mollenkopf; Volker Brinkmann; Stefan H E Kaufmann
Journal:  Eur J Immunol       Date:  2014-06-24       Impact factor: 5.532

Review 4.  Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences.

Authors:  Meg L Donovan; Thomas E Schultz; Taylor J Duke; Antje Blumenthal
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

Review 5.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.

Authors:  Kai Ling Chin; Fadhilah Zulkipli Anis; Maria E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  J Immunol Res       Date:  2017-06-20       Impact factor: 4.818

Review 6.  Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.

Authors:  Bas C Mourik; Erik Lubberts; Jurriaan E M de Steenwinkel; Tom H M Ottenhoff; Pieter J M Leenen
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

Review 7.  Type I interferons in tuberculosis: Foe and occasionally friend.

Authors:  Lúcia Moreira-Teixeira; Katrin Mayer-Barber; Alan Sher; Anne O'Garra
Journal:  J Exp Med       Date:  2018-04-17       Impact factor: 17.579

Review 8.  Host-directed therapies for bacterial and viral infections.

Authors:  Stefan H E Kaufmann; Anca Dorhoi; Richard S Hotchkiss; Ralf Bartenschlager
Journal:  Nat Rev Drug Discov       Date:  2017-09-22       Impact factor: 84.694

9.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.

Authors:  Li Zhang; Xiuju Jiang; Daniel Pfau; Yan Ling; Carl F Nathan
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 17.579

10.  High incidence of tuberculosis in patients treated for hepatitis C chronic infection.

Authors:  Silvia Naomi de Oliveira Uehara; Christini Takemi Emori; Renata Mello Perez; Maria Cassia Jacintho Mendes-Correa; Adalgisa de Souza Paiva Ferreira; Ana Cristina de Castro Amaral Feldner; Antonio Eduardo Benedito Silva; Roberto José Carvalho Filho; Ivonete Sandra de Souza E Silva; Maria Lucia Cardoso Gomes Ferraz
Journal:  Braz J Infect Dis       Date:  2016-02-09       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.